Back to Results

Mesoblast Ltd (MEOBF)

Featured in Bullish Trend Stocks High-Growth Small-Cap Stocks

Mesoblast Ltd is an Australia-based biotechnology company focused on regenerative medicine. Its research platform uses mesenchymal lineage cells, a type of specialized cell used in the company’s development programs. The company is working on several clinical-stage candidates, including Remestemcel-L, which is being studied in Phase III trials for inflammatory conditions such as steroid-refractory acute graft versus host disease, biologic-refractory inflammatory bowel disease, ulcerative colitis, Crohn’s disease, chronic heart failure, and chronic low back pain linked to degenerative disc disease. It is also advancing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Mesoblast has collaborations with Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal covering selected cell therapy programs. Founded in 2004, the company is headquartered in Melbourne, Australia, and its ordinary shares trade on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-MEOB.F
$1.83
-3.8% Downside
Fair
Not available
Not available
Good
0.0%
November 25, 2026
3.3x
15.6x
1.901 B
1.896 B
6.3%
64.9%
-8.7
77.7%
Valuation • Fair Value

Mesoblast Ltd (OTC-MEOB.F) Fair Value by Valuation Model

Review the available estimates for Mesoblast Ltd (OTC-MEOB.F), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.83

Estimated downside of 3.8% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.43

Discounted cash flow valuation reference.

Comps Fair Value

$1.33

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Mesoblast Ltd (OTC-MEOB.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Mesoblast Ltd (OTC-MEOB.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

120.3 M

Current operating scale indicator.

Revenue Forecast

179 M

Forward revenue estimate.

EBITDA

-44.605 M

Current operating profitability reference.

EBITDA Forecast

-37.114 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Mesoblast Ltd (OTC-MEOB.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Mesoblast Ltd (OTC-MEOB.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

2.00

Higher caution zone on this screen.

Altman Z-Score

-8.7

Lower score that deserves closer risk review.

FCF / Net Income

77.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Mesoblast Ltd (OTC-MEOB.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Mesoblast Ltd (OTC-MEOB.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 25, 2026

Days to Earnings

69

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Mesoblast Ltd (OTC-MEOB.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Mesoblast Ltd (OTC-MEOB.F) Stock FAQ

Data-supported answers about Mesoblast Ltd (OTC-MEOB.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.83
Estimated downside 3.8%
Valuation Rating
Overvalued
Estimated downside of 3.8%
Financial Health
Good
Current financial-health read

The current fair value estimate for Mesoblast Ltd (OTC-MEOB.F) is $1.83. This implies an estimated downside of 3.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 3.8% versus the current market price.

The current financial health read for Mesoblast Ltd (OTC-MEOB.F) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Mesoblast Ltd (OTC-MEOB.F) is November 25, 2026.

The latest available data indicates no current dividend yield for Mesoblast Ltd (OTC-MEOB.F).

The current market capitalization listed for Mesoblast Ltd is 1.901 B.

The current enterprise value listed for Mesoblast Ltd is 1.896 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Mesoblast Ltd is OTC-MEOB.F, and the stock is listed on OTC Markets.

Mesoblast Ltd (OTC-MEOB.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Mesoblast Ltd is 6.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Mesoblast Ltd is 64.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 463.9 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 203.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 183.1 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.1 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 77.349 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 60.916 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 58.137 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 49.779 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.993 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.577 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.029 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.916 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.582 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.769 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.287 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.073 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.38 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.286 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.267 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 15.197 B